NCT05643885View on ClinicalTrials.gov

A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

CompletedOBSERVATIONAL
Enrollment

7,304

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

August 30, 2024

Study Completion Date

August 30, 2024

Conditions
Thromboembolism
Trial Locations (1)

10017

Pfizer Investigational, New York

Sponsors

Lead Sponsor

Pfizer

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Pfizer

INDUSTRY

NCT05643885 - A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer | Biotech Hunter | Biotech Hunter